Isomorphic Labs Secures $600 Million to Advance AI-Driven Drug Discovery
Isomorphic Labs, a biotech company focused on AI-first drug design and development, has announced the close of its first external funding round, raising $600 million. The investment was led by Thrive Capital with participation from GV and additional backing from existing investor Alphabet.
The funding is intended to transform the pharmaceutical sector by leveraging artificial intelligence to speed up the discovery and development of new treatments for patients globally
Expanding AI Drug Design Capabilities
Founded by Sir Demis Hassabis, also the CEO of Google DeepMind, Isomorphic Labs is developing an advanced AI drug design platform that integrates multiple AI models to target a broad range of diseases. The company’s mission is to create a unified AI system that can transform biomedical research and bring new therapies to market faster and more efficiently.
Hassabis said, “We're excited to bring together a top-tier investor group with deep AI and life sciences expertise as we aim to transform this industry through an interdisciplinary approach”
He added, “This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI"
Also read: Crusoe Secures $225M Credit Facility from Upper90 to Expand AI Cloud Platform
Notable Partnerships and Breakthroughs
Isomorphic Labs has already made notable progress with its AI models. A prime example is AlphaFold 3, created in collaboration with Google DeepMind, which accurately predicts the structure and interactions of biological molecules, key to understanding how potential drugs will work.
The company has also established major collaborations with pharmaceutical leaders, including Novartis and Eli Lilly, and is working on internal drug programs targeting oncology and immunology.
